Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists

MLA

Nisio, Marcello Di, et al. “Risk of Major Bleeding in Patients with Venous Thromboembolism Treated with Rivaroxaban or with Heparin and Vitamin K Antagonists.” Thrombosis and Haemostasis, vol. 115, no. 2, Feb. 2016, pp. 424–32. EBSCOhost, https://doi.org/10.1160/th15-06-0474.

APA

Nisio, M. D., Ageno, W., Rutjes, A. W. S., Pap, A. F., & Büller, H. R. (2016). Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thrombosis and Haemostasis, 115(2), 424–432. https://doi.org/10.1160/th15-06-0474

Chicago

Nisio, Marcello Di, Walter Ageno, Anne W. S. Rutjes, Akos F. Pap, and Harry R. Büller. 2016. “Risk of Major Bleeding in Patients with Venous Thromboembolism Treated with Rivaroxaban or with Heparin and Vitamin K Antagonists.” Thrombosis and Haemostasis 115 (2): 424–32. doi:10.1160/th15-06-0474.